Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429018 | 1.00 | ALDH1A1 (0.37) | ALDH1A1CYP2C19KDM4EGAATSHR | |
| SCHEMBL5263549 | 0.74 | ALDH1A1 (0.35) | ALDH1A1KDM4EGAATSHRSMN1; SMN2 | |
| SCHEMBL5263541 | 0.74 | ALDH1A1 (0.35) | ALDH1A1KDM4EGAATSHRSMN1; SMN2 | |
| SCHEMBL429986 | 0.70 | ALDH1A1 (0.45) | ALDH1A1KDM4EGAATSHRSMN1; SMN2 | |
| SCHEMBL9840526 | 0.64 | L3MBTL1 (0.40) | ALDH1A1KDM4ETSHRSMN1; SMN2 | |
| SCHEMBL3190023 | 0.62 | CYP2C19 (0.39) | ALDH1A1CYP2C19TSHR | |
| SCHEMBL430744 | 0.62 | MAPT (0.47) | ALDH1A1KDM4ETSHRSMN1; SMN2 | |
| SCHEMBL5261603 | 0.61 | KMT2A (0.41) | ALDH1A1CYP2C19KDM4ETSHRSMN1; SMN2 | |
| SCHEMBL5261599 | 0.61 | KMT2A (0.41) | ALDH1A1CYP2C19KDM4ETSHRSMN1; SMN2 | |
| SCHEMBL428326 | 0.61 | GPR35 (0.42) | ALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | ALDH1A1 257/4885CYP2C19 350/4885KDM4E 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.